Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SAP SE (SAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SAP SE — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while SAP SE trades at $158.44 (market cap $182.93B). The key difference: SAP SE is far larger — about 4.6× Alnylam Pharmaceuticals, Inc.'s market cap, and SAP SE pays a 1.86% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SAP | |
|---|---|---|
Market Cap | $39.89B | $182.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $308.61 |
52-Week Low | $278.09 | $148.06 |
Enterprise Value | $38.15B | $180.44B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SAP trades at $157.86, down 0.38% on the day, amid a bearish technical signal but strong fundamental performance. The stock has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $2.05. Revenue grew to $36.80B in 2025, with a net income margin of 19.58%, while the company maintains robust cash flow from operations of $9.16B. Recent news highlights SAP's resolution of EU antitrust concerns and strategic focus on AI investments to drive future growth.
The outlook for SAP is positive based on solid fundamentals and analyst consensus, with a price target of $228.50 implying significant upside. However, risks include competitive pressures, execution of AI initiatives, and macroeconomic volatility. Investors should weigh the strong profitability and growth trajectory against near-term technical weakness and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
